(Press-News.org) LONDON, UK - 30 August, 2015: In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.
The study, presented today at ESC Congress 2015, "demonstrates the cardiovascular safety of lixisenatide", reported Eldrin F. Lewis, MD, MPH, a member of the ELIXA trial's executive committee, a physician in the Cardiovascular Medicine Division at Brigham and Women's Hospital and an associate professor at Harvard Medical School, in Boston, USA.
The results of the ELIXA trial, originally presented in June at the American Diabetes Association, are the first to be reported on the CV safety outcomes of a glucagon-like peptide 1 (GLP-1) receptor agonist.
"Prior studies have established that patients with type 2 diabetes are at higher risk for incident cardiovascular disease than people who do not have type 2 diabetes, and some glucose-lowering drugs have been associated with increased risk of cardiovascular disease," said Dr. Lewis, explaining that this has prompted both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) and to establish guidelines for clinical trials that would ensure cardiovascular safety in glucose-lowering therapies.
The ELIXA trial was powered to establish safety (non-inferiority) and superiority of lixisendatide versus placebo. Although it was not able to establish the superiority of lixisenatide over placebo for CV safety, "the neutral effects on cardiovascular events are all within the limits of the EMA's and FDA's guidelines," commented Dr. Lewis. "In addition, lixisenatide provided a modest benefit in terms of weight gain."
The study included 6,068 patients (mean age 60.3 years) with type 2 diabetes and a history of myocardial infarction (83%) or hospitalisation for unstable angina (17%) within the past 180 days.
The patients were randomised to receive daily injections of either lixisenatide or placebo and followed for a minimum of 10 months to measure the primary outcome: a composite of cardiovascular death, heart attacks, stroke, and hospitalisation for unstable angina. Important additional outcome measures included all-cause death and heart failure hospitalisations.
This outcome occurred in 13.4 percent of the lixisenatide group compared to 13.2 percent of the placebo group, with the hazard ratio of 1.02 and a 95% confidence interval that was "well below the standard set by the FDA," noted Dr. Lewis.
Lixisenatide was also safe in patients with a history of heart failure. Among patients with a history of chronic heart failure prior to randomisation, approximately 10% had a hospitalisation for heart failure during follow-up, compared to 2.4% of patients without a history of chronic heart failure.
"The hazard ratio was similar between lixisenatide and placebo demonstrating similar CV safety of lixisenatide in this population," he said.
However, patients who were hospitalised for heart failure had a risk of all-cause death that was 9-fold greater than those who were not hospitalised for heart failure. "This excess mortality suggests that these are important events to capture among patients with diabetes," said Dr. Lewis.
INFORMATION:
LONDON, UK - 30 August, 2015: Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows.
The findings, presented today at ESC Congress 2015, "provide reassurance to patients and prescribers about the cardiovascular safety of sitagliptin" - a dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin - according to Paul ...
London, UK - 31 Aug 2015: Depressed patients have more frequent chest pain even in the absence of coronary artery disease, according to results from the Emory Cardiovascular Biobank presented at ESC Congress today by Dr Salim Hayek, a cardiologist at Emory University School of Medicine in Atlanta, Georgia, US.1 The findings suggest that pain and depression may share a common neurochemical pathway.
"Depression is a common and well recognised risk factor for the development of heart disease," said Dr Hayek. "Patients with known heart disease and depression tend to experience ...
London, UK - 31 Aug 2015: Retrieval of larger thrombi during intra arterial treatment (IAT) is associated with improved neurological recovery after acute ischaemic stroke, according to a sub study of the MR CLEAN trial presented at ESC Congress today by Dr Anouchska Autar, PhD candidate at the Erasmus Medical Centre in Rotterdam, the Netherlands.1
"Acute ischaemic strokes occur when a blood clot, also called a thrombus, embolises to the brain where it restricts the flow of blood," said Dr Autar. "MR CLEAN was the first trial to show the benefit of IAT to remove blood ...
India's bread basket, the Indo-Gangetic Plains (IGP), have been classified as a "hot spot" for air pollution. A recent study from the University of Eastern highlights the current status of ozone research in the IGP region, which is agriculturally important and densely populated.
To study adverse effects of ozone, field experiments were conducted with local crop cultivars of mustard (Brassica campestris L.) and rice (Oryza sativa L.), and various growth, physiological (gas-exchange), biochemical and yield parameters were studied throughout the growing season. Ethylenediurea ...
Many volcanoes are located in densely settled areas. Every time one of these becomes active, large populations are put at risk. Hence, one of the primary goals of the current generation of volcanologists is to develop tools that can accurately predict when volcanoes will erupt. In the case of an impending eruption, these tools are of key importance to those charged with making decisions about what action to take and when. "However, the tools available for predicting eruptions are still in their infancy. We can't always successfully predict an eruption as we lack an understanding ...
Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer. If MACC1 expression is low, the patients have a good chance that surgery will prolong survival. By contrast, if the gene is ...
London, UK - 30 Aug 2015: Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace. 2
"This is the first study to show better outcomes using the 2012 ESC guidelines on atrial fibrillation," said principal investigator Professor Gregory YH Lip, from the University of Birmingham, UK and Aalborg University, Denmark.3 "This is novel ...
London, UK - 31 Aug 2015: Respiratory infection is associated with a four-fold increased risk of in-hospital cardiovascular mortality after acute myocardial infarction (AMI), according to research presented at ESC Congress today by Dr Catarina Quina-Rodrigues, a cardiologist at Hospital de Braga in Portugal.1 The findings highlight the importance of diagnostic alertness for respiratory infections in AMI patients so that therapeutic measures can be promptly taken.
"Cardiovascular disease remains the leading cause of death in Europe and around the world," said Dr Quina-Rodrigues. ...
London, UK - 31 Aug 2015: Women aged 45 years and under with diabetes have a six-fold risk of heart attack, according to research presented at ESC Congress today.1 The study in more than 7 000 women also found that young women who had a heart attack (myocardial infarction, MI) were more likely to be smokers than older women with MI.
"Cardiovascular diseases (CVDs) affect mainly the elderly, but for many years an increase in incidence has been observed in young people as well, regardless of gender," said Professor Hanna Szwed, last author and head of the 2nd Department ...
TORONTO, ON - It's like something out of a science-fiction movie - time-lapse photography showing how wounds in embryos of fruit flies heal themselves. The images are not only real; they shed light on ways to improve wound recovery in humans.
Researchers at the University of Toronto (U of T) and the Hospital for Sick Children have found that the process of endocytosis - how cells "eat" by absorbing molecules - drives rapid embryonic healing.
"Endocytosis removes the junctions between wounded and non-wounded cells, to allow the non-wounded cells to move and stretch over ...
